Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Daniel B. Maselli, Michael Camilleri
Advances in experimental medicine and biology (2020), pp. 171-192
Closed Access | Times Cited: 144

Showing 26-50 of 144 citing articles:

Management of chronic kidney disease: The current novel and forgotten therapies
Ákos Pethő, Mihály Tapolyai, Éva Csongrádi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100354-100354
Open Access | Times Cited: 8
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
Sebastian Badulescu, Aniqa Tabassum, Gia Han Le, et al.
Physiology & Behavior (2024) Vol. 283, pp. 114622-114622
Open Access | Times Cited: 8
Intestinal glucagon-like peptide-1: A new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice
Fang‐Xin Jin, Yan Wang, Min‐Ne Li, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 8, pp. 1764-1777
Open Access | Times Cited: 8
A Case of Intussusception With Bowel Obstruction in a Gastric Roux-en-Y Patient Prescribed Semaglutide
S. Pavuluri, Ahmad Toumar, Andrew J. Duffy
Journal of the American College of Emergency Physicians Open (2025) Vol. 6, Iss. 2, pp. 100045-100045
Closed Access | Times Cited: 1
GLP-1 receptor agonist as a modulator of innate immunity
Jun Chen, Aihua Mei, Yingying Wei, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss
Marissa Weber, Ingharan J. Siddarthan, Patricia Fogarty Mack
British Journal of Anaesthesia (2023) Vol. 131, Iss. 2, pp. e37-e39
Open Access | Times Cited: 20
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Minjeong Park, Hayeon Kim, Myeong Gyu Kim, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 693-704
Open Access | Times Cited: 19
Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study
Benjamin D. Liu, Sharon C. Udemba, Katherine Liang, et al.
Gut (2023) Vol. 73, Iss. 2, pp. 246-254
Closed Access | Times Cited: 18
How do GLP-1 drugs work for weight loss . . . and everything else?
Marianne Guenot
BMJ (2024), pp. q1767-q1767
Closed Access | Times Cited: 7
Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center
Ernesto Robalino Gonzaga, Aimen Farooq, Abdul Mohammed, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5403-5403
Open Access | Times Cited: 6
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
Adriana D. Oprea, Guillermo E. Umpierrez, BobbieJean Sweitzer, et al.
Anesthesiology (2024) Vol. 141, Iss. 6, pp. 1141-1161
Closed Access | Times Cited: 6
Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications
Lizeth Cifuentes, Michael Camilleri, Andrés Acosta
Nutrients (2021) Vol. 13, Iss. 4, pp. 1158-1158
Open Access | Times Cited: 35
Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists
Mincho Marroquin-Harris, Benjamin L Olesnicky
Anaesthesia (2023) Vol. 78, Iss. 12, pp. 1524-1524
Open Access | Times Cited: 16
Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease
Sundararajan Mahalingam, Ramesh Bellamkonda, Madan Kumar Arumugam, et al.
Biochemical Pharmacology (2023) Vol. 213, pp. 115613-115613
Open Access | Times Cited: 13
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Amedeo Tirandi, Fabrizio Montecucco, Federico Carbone, et al.
Polskie Archiwum Medycyny Wewnętrznej (2024)
Open Access | Times Cited: 5
Effect of ultrasonic degradation on the physicochemical characteristics, GLP-1 secretion, and antioxidant capacity of Polygonatum cyrtonema polysaccharide
Peng Liu, Ya-Min Qin, Jin-Yang Shi, et al.
International Journal of Biological Macromolecules (2024) Vol. 274, pp. 133434-133434
Closed Access | Times Cited: 5
Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study
Haider Ghazanfar, Nismat Javed, A Qasim, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 26, pp. 3221-3228
Open Access | Times Cited: 5
Glucagon-like Peptide-1 Receptor Agonists and Capsule Endoscopy in Patients with Diabetes: A Matched Cohort Study
Tarek Odah, Asrita Vattikonda, Mark E. Stark, et al.
Gastrointestinal Endoscopy (2024)
Closed Access | Times Cited: 5
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
M Gabe, Astrid Breitschaft, Filip K. Knop, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4480-4489
Closed Access | Times Cited: 5
Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use
Sarah L. Kittner, Ashley L. Talbott, Susan R. Vishneski, et al.
JBJS Case Connector (2023) Vol. 13, Iss. 4
Closed Access | Times Cited: 11
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment
Mansour Tobaiqy
Pharmacological Reports (2024) Vol. 76, Iss. 5, pp. 981-990
Closed Access | Times Cited: 4
The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects
Piotr Krajewski, Aleksandra Złotowska, Jacek C. Szepietowski
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6292-6292
Open Access | Times Cited: 4
European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management
Carolina Malagelada, Jutta Keller, Daniel Sifrim, et al.
United European Gastroenterology Journal (2025)
Open Access
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials
Domenica Rubino, Sue D. Pedersen, Lisa Connery, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
Ronald Goldenberg, Jeremy Gilbert, Robyn L. Houlden, et al.
Current Medical Research and Opinion (2025), pp. 1-17
Closed Access

Scroll to top